Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of…
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, (the “Company”, “we”, “our”) a leader in slide-free, tissue-to-digital™ pathology…
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a…
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces…
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate…
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo Cytek today unveiled the Cytek Aurora™ Evo system,…
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management…
CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced…
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May…